Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chiauranib in Advanced Solid Tumors and SCLC
NCT05271292Phase 2Recruiting
- Sponsor
- Akeso, Inc.
- Start
- Aug 2022
- Primary completion
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of chiauranib in solid tumor (advanced stage) and small cell lung cancer (SCLC) (4 arms), sponsored by Akeso, Inc. Primary endpoints: Incidence of adverse events (AEs) and other safety parameters, Incidence and characteristics of DLTs at 34 days and 1 more. Started Aug 2022; status: recruiting.
02
Drugs
chiauranib
03
Conditions
solid tumor (advanced stage)small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT05271292.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05271292.